| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/ATVBAHA.107.159160 |
| P698 | PubMed publication ID | 18096829 |
| P50 | author | David R Greaves | Q40643814 |
| Eileen McNeill | Q41774481 | ||
| Keith Channon | Q56420294 | ||
| Marianna Papaspyridonos | Q117232691 | ||
| P2093 | author name string | Alberto Smith | |
| Kevin G Burnand | |||
| Joe P de Bono | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macrophage | Q184204 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 433-440 | |
| P577 | publication date | 2007-12-20 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction | |
| P478 | volume | 28 |
| Q35007422 | Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants |
| Q48879804 | Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. |
| Q58608459 | Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways |
| Q39033572 | Candida albicans and Candida parapsilosis rapidly up-regulate galectin-3 secretion by human gingival epithelial cells. |
| Q36073585 | Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacDiNAc) based on galactose oxidase treatment |
| Q34102031 | Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure |
| Q47969856 | Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease? |
| Q37644081 | Do galectins play a role in venous thrombosis? a review. |
| Q38254055 | Evolving mechanistic insights into galectin functions |
| Q42077799 | Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways |
| Q47653100 | Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update |
| Q58083295 | Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients |
| Q90152813 | Galectin-3 Is a Potential Mediator for Atherosclerosis |
| Q92801292 | Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension |
| Q36956715 | Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites |
| Q89313843 | Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study |
| Q42569059 | Galectin-3 and new-onset CKD: marker or mediator? |
| Q40057919 | Galectin-3 and risk of ischemic stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort. |
| Q49400435 | Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study |
| Q33754984 | Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. |
| Q37707674 | Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension |
| Q33577541 | Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study |
| Q35026202 | Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis |
| Q41716070 | Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study. |
| Q58094533 | Galectin-3and risk of cardiovascular events and all-cause mortality in type 2 diabetes mellitus |
| Q51746575 | Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study. |
| Q96603339 | INCREASED SERUM LEVELS OF GALECTIN-9 IN PATIENTS WITH CHIKUNGUNYA FEVER |
| Q45880373 | Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition. |
| Q37183047 | Loss of galectin-3 decreases the number of immune cells in the subventricular zone and restores proliferation in a viral model of multiple sclerosis. |
| Q37384489 | Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. |
| Q89463384 | Macrophage subsets in atherosclerosis as defined by single-cell technologies |
| Q55230733 | Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. |
| Q58722306 | Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease |
| Q48155995 | Mouse Thyroid Gland Changes in Aging: Implication of Galectin-3 and Sphingomyelinase |
| Q24651908 | N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin |
| Q90416246 | Nonalcoholic Fatty Liver Disease |
| Q48156451 | Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction |
| Q99614770 | Plasma APE1/Ref-1 Correlates with Atherosclerotic Inflammation in ApoE-/- Mice |
| Q40060474 | Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease |
| Q50133781 | Possible Role of Inflammation and Galectin-3 in Brain Injury after Subarachnoid Hemorrhage |
| Q28534290 | Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease |
| Q35533394 | Regulation of ozone-induced lung inflammation and injury by the β-galactoside-binding lectin galectin-3. |
| Q35969291 | Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production |
| Q36456913 | Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication |
| Q38540889 | Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential |
| Q38568205 | The Current and Potential Clinical Relevance of Heart Failure Biomarkers |
| Q61187714 | The potential role of leptin in the vascular remodeling associated with obesity. |
| Q35075568 | Therapy of experimental NASH and fibrosis with galectin inhibitors |
| Q35553234 | Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. |
| Q37443866 | Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation |
| Q36924004 | Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine. |
Search more.